Sustained, Powerful Outcomes In Over 5,000 Resolute Patients

Resolute™ DES Showed Low 0.3% VLST Rate in More Than 5000 Patients

RESOLUTE Pooled* Stent Thrombosis Rate to Three Years

Manoharan, G. Pooled analysis of clinical events from prospective trials of the Resolute zotarolimus-eluting stent: three year outcomes of 5130 patients. ACC. 2013. Post-hoc RESOLUTE Pooled analysis was not powered for the analysis shown.
Outcomes remain consistent when adjusted for duration of DAPT and other variables.
*RESOLUTE FIM, RESOLUTE All-Comers, RESOLUTE International, RESOLUTE US, RESOLUTE Japan

 

Powerful Performance in More Than 5000 Patients*

TLF and Components at Three Years

Target lesion failure (TLF) is defined as cardiac death, target vessel MI and clinically indicated TLR
Manoharan, G. Pooled analysis of clinical events from prospective trials of the Resolute zotarolimus-eluting stent: three year outcomes of 5130 patients. ACC. 2013. Post-hoc RESOLUTE Pooled analysis was not powered for the analysis shown.
Outcomes remain consistent when adjusted for duration of DAPT and other variables.
*RESOLUTE FIM, RESOLUTE All-Comers, RESOLUTE International, RESOLUTE US, RESOLUTE Japan